Contact Us
  • Choose License Type

Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,566.5 million in 2020 and is expected to exhibit a CAGR of 9.8% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The companies are focusing on adoption of inorganic growth strategies such as collaboration and acquisition, in order to expand their product portfolio and strengthen their presence in the market, which is expected to drive growth of the mucopolysaccharidosis (MPS) treatment market over the forecast period. For instance, on August 11, 2020, Sarepta Therapeutics Inc. and the University of Florida announced a strategic collaboration to enable cutting-edge research for novel genetic medicines for the treatment of rare genetic diseases such as mucopolysaccharidosis.

Global Mucopolysaccharidosis (MPS) Treatment Market – Impact of Coronavirus (Covid-19) Pandemic

Extensive research and development of novel products is expected drive the market growth despite the COVID-19 crisis. For instance, in July 2020, Abeona Therapeutics Inc. announced that two ongoing MPS III Phase 1/2 clinical trials of its investigational adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101, have showed positive effects on the patients, with additional enrollment expected in the programs in the coming weeks.

Moreover, governments are taking various initiatives to combat COVID-19. For instance, in May 2020, the Centers for Disease Control and Prevention started working with the All-of-Government and All-of-America Approach to increase testing capacity and availability to improve case detection and contact tracing though all states in the U.S., and plans to re-open America by removing the lockdown.

Browse 35 Market Data Tables and 34 Figures spread through 198 Pages and in-depth TOC on “Mucopolysaccharidosis (MPS) Treatment Market”- Global Forecast to 2027, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global mucopolysaccharidosis (MPS) treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/mucopolysaccharidosis-treatment-market-4184

Key players operating in the market are providing special reimbursement package for patients. For instance, Takeda Pharmaceutical Company Limited initiated Takeda OnePath Assistance Program, which offers personalized support to the patients. The program takes care of patients by making medicines available to the patients for their treatment, which are manufactured by Takeda Pharmaceutical Company Limited. The program also provides insurance in order to cover the expense of the patients’ treatment. The program also supports patients suffering from Hunter Syndrome (MPS II). Thus, providing reimbursements increase the customer base, which strengthens the position of the company in the global market.                                

Key Takeaways of the Global Mucopolysaccharidosis (MPS) Treatment Market:

  • The global mucopolysaccharidosis (MPS) treatment market is expected to exhibit a CAGR of 9.8% over the forecast period, owing to increasing agreements and acquisitions by market players. For instance, on August 11, 2020, Sarepta Therapeutics Inc. and the University of Florida announced a strategic collaboration to enable cutting-edge research for novel genetic medicines for the treatment of rare genetic diseases such as mucopolysaccharidosis.
  • Among treatment, the enzyme replacement therapy segment held a dominant position in the mucopolysaccharidosis (MPS) treatment market in 2019, owing to increasing approval for enzyme replacement therapy for mucopolysaccharidosis (MPS) treatment. For instance, in October 2018, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, received Brazil’s National Health Surveillance Agency (ANVISA) approval for its Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome) for patients of all ages.
  • Key players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner